Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
Капзатраты
A1 A2
PFE
FY2026 Q2
Повышен
Отчётный звонок Pfizer, Inc.
Вывод Buzzberg
Company raises revenue guidance despite lower COVID revenues
Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations.
Вывод Buzzberg Company raises revenue guidance despite lower COVID revenues Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations. Читать полный анализСвернуть анализ
Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations.
- Non-COVID business delivered 5% operational revenue growth in Q2; acquired products grew 27% operationally.
- Initiated Phase 3 trials for its bispecific antibody, including a head-to-head vs. Dupixent powered for superiority.
- Updated Phase 1 data in 1L NSCLC shows ~82% ORR for its ADC+anti-PD-1 combo, supporting its Phase 3 program.
Выручка$15.034B+4% к/к
EPS$0.77+3% к/к
Валовая маржа72.78%Факт
Операционная маржа31.3%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Growth
Acquired product revenues grew 27% operationally, excluding one-time items
Costs
Additional $2.5 billion net cost savings expected from 2027-2029
Показать ещё 3 тезиса
Capital Allocation
Dividend to be maintained and eventually grow
Pipeline
Vera binitide shows potential for monthly obesity therapy with comparable efficacy
Pipeline
Telrecamig to be tested head-to-head against Dupixent in atopic dermatitis
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $15.034B | +4% к/к |
| EPS | $0.77 | +3% к/к |
| Валовая маржа | 72.78% | Факт |
| Операционная маржа | 31.3% | Факт |
| Свободный денежный поток | $0.302B | Факт |
| Капзатраты | $0.533B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $2.80–$3.00 | $2.90 | Подтверждён |
| Выручка | FY2026 | $60.5B–$62.5B | $61.5B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management repeatedly highlighted strong execution, raised revenue guidance, and expressed confidence in future growth and dividend maintenance, despite acknowledging challenges like COVID revenue declines and pipeline setbacks.
Оценка AI от менеджмента
Management views AI as a structural transformation opportunity, already seeing benefits in manufacturing cost reduction, yield expansion, commercial field force effectiveness, and marketing approaches, with ambitions to build an AI-native R&D organization.
Инвестиции и мощности
Pfizer is expanding its manufacturing optimization program, expecting total net cost savings of approximately $3 billion through 2029, with additional savings from the next phase focused on network structure changes, product portfolio enhancement, and operational efficiency.
все упомянутые компании ниже: 8
Компаниис момента звонка
Партнёры
Партнёры
Cécile Guégan
Pfizer acknowledges BMS's public guidance on Eliquis growth as a key driver for its own raised revenue guidance.
Доказательства
“with a driver that our partner BMS has described”
Партнёры
Chris Boshoff
Pfizer highlights the scale of development for the in-licensed bispecific, signaling activity and progress on the asset.
Доказательства
“Since in-licensing from 3SV about a year ago, we started nine trials including two Phase III studies”
Конкуренты
Конкуренты
Chris Boshoff
Pfizer's model projects its candidate as potentially superior to Novo's semaglutide in weight loss, a direct competitive claim.
Доказательства
“the analysis suggests barabenotype can deliver weight loss comparable to desepatite and potentially better than semaglutide.”
Конкуренты
Chris Boshoff
Pfizer highlights its bispecific's Phase 2 data against Regeneron's ivonescimab, suggesting a potential competitive advantage.
Доказательства
“these data compare favorably with Ivernissimab Phase III results in this population”
Конкуренты
Chris Boshoff
Pfizer references Merck's pembrolizumab as a benchmark for combination opportunity, emphasizing the clinical utility of the regimen.
Доказательства
“These data align with the ability of the DOTIN ADCs to induce immunogenic cell death and thereby potentially synergize with anti-PD-1 agents such as pembrolizumab.”
Конкуренты
Chris Boshoff
Pfizer reports a Phase 1/2 trial design for its once-monthly GLP-1 and amylin combination is focused on tolerability, positioning it as a potential differentiated therapy. — A tolerable monthly combination could provide a significant convenience advantage over weekly rivals like Lilly's Zepbound.
Доказательства
“it is encouraging that berubenatide achieved week 28 efficacy that was similar to tesepatite's medium dose of 10 mg in the SUMMOUND-1 study”
Цепочка поставок
Цепочка поставок
Chris Boshoff
Pfizer plans to start a Phase 3 trial for a bispecific antibody directly vs. Dupixent, powered for superiority, in a head-to-head setting. — A potential weekly alternative to Dupixent could challenge Sanofi's franchise in atopic dermatitis and asthma.
Доказательства
“Indeed, this will be one of the first phase three trials that will be head against DUPI and powered for superiority against DUPI.”
Внешние сигналы
Альфа цепочки поставок · 2с момента звонка
Pfizer plans to start a Phase 3 trial for a bispecific antibody directly vs. Dupixent, powered for superiority, in a head-to-head setting.
Pfizer reports a Phase 1/2 trial design for its once-monthly GLP-1 and amylin combination is focused on tolerability, positioning it as a potential differentiated therapy.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 8. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.